$GYHT Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in HALOZYME THERAPEUTICS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in HALOZYME THERAPEUTICS, INC.. Get notifications about new insider transactions in HALOZYME THERAPEUTICS, INC. for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 07 2021 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Option Exercise | M | 14.66 | 50,000 | 733,000 | 400,000 | |
Jun 07 2021 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Sell | S | 39.66 | 50,000 | 1,982,950 | 537,160 | 587.2 K to 537.2 K (-8.52 %) |
Jun 07 2021 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Buy | M | 14.66 | 50,000 | 733,000 | 587,160 | 537.2 K to 587.2 K (+9.31 %) |
May 06 2021 | GYHT | HALOZYME THERAPEUT ... | Posard Matthew L. | Director | Grant | A | 0.00 | 5,230 | 0 | 128,983 | 123.8 K to 129 K (+4.23 %) |
May 06 2021 | GYHT | HALOZYME THERAPEUT ... | MATSUI CONNIE | Director | Grant | A | 0.00 | 5,230 | 0 | 213,983 | 208.8 K to 214 K (+2.51 %) |
May 06 2021 | GYHT | HALOZYME THERAPEUT ... | Henderson Jeffrey William | Director | Grant | A | 0.00 | 5,230 | 0 | 52,839 | 47.6 K to 52.8 K (+10.99 %) |
May 06 2021 | GYHT | HALOZYME THERAPEUT ... | Daly James M | Director | Grant | A | 0.00 | 5,230 | 0 | 26,232 | 21 K to 26.2 K (+24.90 %) |
May 06 2021 | GYHT | HALOZYME THERAPEUT ... | Connaughton Bernadette | Director | Grant | A | 0.00 | 5,230 | 0 | 32,013 | 26.8 K to 32 K (+19.53 %) |
May 06 2021 | GYHT | HALOZYME THERAPEUT ... | BIZZARI JEAN-PIERRE | Director | Grant | A | 0.00 | 5,230 | 0 | 87,544 | 82.3 K to 87.5 K (+6.35 %) |
May 03 2021 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Option Exercise | M | 11.29 | 11,311 | 127,701 | 0 | |
May 03 2021 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Buy | M | 11.29 | 11,311 | 127,701 | 134,111 | 122.8 K to 134.1 K (+9.21 %) |
Apr 14 2021 | GYHT | HALOZYME THERAPEUT ... | Kelley Kenneth J | Director | Sell | S | 45.00 | 5,000 | 225,000 | 179,833 | 184.8 K to 179.8 K (-2.71 %) |
Apr 05 2021 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Option Exercise | M | 14.66 | 50,000 | 733,000 | 500,000 | |
Apr 05 2021 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Sell | S | 42.55 | 50,000 | 2,127,250 | 537,160 | 587.2 K to 537.2 K (-8.52 %) |
Apr 05 2021 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Buy | M | 14.66 | 50,000 | 733,000 | 587,160 | 537.2 K to 587.2 K (+9.31 %) |
Apr 01 2021 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Option Exercise | M | 11.29 | 28,689 | 323,899 | 11,311 | |
Apr 01 2021 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Sell | S | 42.79 | 18,994 | 812,829 | 122,800 | 141.8 K to 122.8 K (-13.40 %) |
Apr 01 2021 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Sell | S | 42.11 | 9,695 | 408,208 | 141,794 | 151.5 K to 141.8 K (-6.40 %) |
Apr 01 2021 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Buy | M | 11.29 | 28,689 | 323,899 | 151,489 | 122.8 K to 151.5 K (+23.36 %) |
Apr 01 2021 | GYHT | HALOZYME THERAPEUT ... | Sun Elaine D | SVP, Chief Financia ... | Option Exercise | M | 0.00 | 10,196 | 0 | 30,600 | |
Apr 01 2021 | GYHT | HALOZYME THERAPEUT ... | Sun Elaine D | SVP, Chief Financia ... | Payment of Exercise | F | 42.43 | 4,059 | 172,223 | 14,018 | 18.1 K to 14 K (-22.45 %) |
Apr 01 2021 | GYHT | HALOZYME THERAPEUT ... | Sun Elaine D | SVP, Chief Financia ... | Buy | M | 0.00 | 10,196 | 0 | 18,077 | 7.9 K to 18.1 K (+129.37 %) |
Mar 01 2021 | GYHT | HALOZYME THERAPEUT ... | Kelley Kenneth J | Director | Sell | S | 46.08 | 500 | 23,042 | 184,833 | 185.3 K to 184.8 K (-0.27 %) |
Mar 01 2021 | GYHT | HALOZYME THERAPEUT ... | Kelley Kenneth J | Director | Sell | S | 45.26 | 4,500 | 203,675 | 185,333 | 189.8 K to 185.3 K (-2.37 %) |
Mar 01 2021 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Sell | S | 46.26 | 6,530 | 302,061 | 122,800 | 129.3 K to 122.8 K (-5.05 %) |
Mar 01 2021 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Sell | S | 45.56 | 11,794 | 537,303 | 129,330 | 141.1 K to 129.3 K (-8.36 %) |
Mar 01 2021 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Option Exercise | M | 14.66 | 50,000 | 733,000 | 550,000 | |
Mar 01 2021 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Sell | S | 46.48 | 33,890 | 1,575,112 | 537,160 | 571.1 K to 537.2 K (-5.93 %) |
Mar 01 2021 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Sell | S | 45.58 | 16,110 | 734,342 | 571,050 | 587.2 K to 571.1 K (-2.74 %) |
Mar 01 2021 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Buy | M | 14.66 | 50,000 | 733,000 | 587,160 | 537.2 K to 587.2 K (+9.31 %) |
Feb 22 2021 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Option Exercise | M | 0.00 | 8,803 | 0 | 0 | |
Feb 22 2021 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Payment of Exercise | F | 48.69 | 4,364 | 212,483 | 141,124 | 145.5 K to 141.1 K (-3.00 %) |
Feb 22 2021 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Buy | M | 0.00 | 8,803 | 0 | 145,488 | 136.7 K to 145.5 K (+6.44 %) |
Feb 22 2021 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Option Exercise | M | 0.00 | 39,354 | 0 | 0 | |
Feb 22 2021 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Payment of Exercise | F | 48.69 | 19,511 | 949,991 | 537,160 | 556.7 K to 537.2 K (-3.50 %) |
Feb 22 2021 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Buy | M | 0.00 | 39,354 | 0 | 556,671 | 517.3 K to 556.7 K (+7.61 %) |
Feb 17 2021 | GYHT | HALOZYME THERAPEUT ... | Matsuda Masaru | SVP, General Counse ... | Option Exercise | A | 0.00 | 13,544 | 0 | 13,544 | |
Feb 17 2021 | GYHT | HALOZYME THERAPEUT ... | Matsuda Masaru | SVP, General Counse ... | Option Exercise | A | 49.84 | 23,311 | 1,161,820 | 23,311 | |
Feb 17 2021 | GYHT | HALOZYME THERAPEUT ... | Sun Elaine D | SVP, Chief Financia ... | Option Exercise | A | 0.00 | 14,898 | 0 | 14,898 | |
Feb 17 2021 | GYHT | HALOZYME THERAPEUT ... | Sun Elaine D | SVP, Chief Financia ... | Option Exercise | A | 49.84 | 25,642 | 1,277,997 | 25,642 | |
Feb 17 2021 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Option Exercise | A | 0.00 | 52,368 | 0 | 52,368 | |
Feb 17 2021 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Option Exercise | A | 49.84 | 90,134 | 4,492,279 | 90,134 | |
Feb 16 2021 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Option Exercise | M | 0.00 | 28,729 | 0 | 28,729 | |
Feb 16 2021 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Payment of Exercise | F | 49.84 | 14,243 | 709,871 | 517,317 | 531.6 K to 517.3 K (-2.68 %) |
Feb 16 2021 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Buy | M | 0.00 | 28,729 | 0 | 531,560 | 502.8 K to 531.6 K (+5.71 %) |
Feb 12 2021 | GYHT | HALOZYME THERAPEUT ... | Matsuda Masaru | SVP, General Counse ... | Option Exercise | M | 0.00 | 4,129 | 0 | 8,258 | |
Feb 12 2021 | GYHT | HALOZYME THERAPEUT ... | Matsuda Masaru | SVP, General Counse ... | Option Exercise | M | 0.00 | 6,257 | 0 | 18,769 | |
Feb 12 2021 | GYHT | HALOZYME THERAPEUT ... | Matsuda Masaru | SVP, General Counse ... | Payment of Exercise | F | 49.84 | 2,047 | 102,022 | 16,578 | 18.6 K to 16.6 K (-10.99 %) |
Feb 12 2021 | GYHT | HALOZYME THERAPEUT ... | Matsuda Masaru | SVP, General Counse ... | Buy | M | 0.00 | 4,129 | 0 | 18,625 | 14.5 K to 18.6 K (+28.48 %) |
Feb 12 2021 | GYHT | HALOZYME THERAPEUT ... | Matsuda Masaru | SVP, General Counse ... | Payment of Exercise | F | 50.60 | 3,203 | 162,072 | 14,496 | 17.7 K to 14.5 K (-18.10 %) |
Feb 12 2021 | GYHT | HALOZYME THERAPEUT ... | Matsuda Masaru | SVP, General Counse ... | Buy | M | 0.00 | 6,257 | 0 | 17,699 | 11.4 K to 17.7 K (+54.68 %) |
Feb 12 2021 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Option Exercise | M | 0.00 | 7,883 | 0 | 15,766 | |
Feb 12 2021 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Option Exercise | M | 0.00 | 8,134 | 0 | 24,399 | |
Feb 12 2021 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Payment of Exercise | F | 49.84 | 2,725 | 135,814 | 133,186 | 135.9 K to 133.2 K (-2.00 %) |
Feb 12 2021 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Buy | M | 0.00 | 7,883 | 0 | 135,911 | 128 K to 135.9 K (+6.16 %) |
Feb 12 2021 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Payment of Exercise | F | 50.60 | 2,906 | 147,044 | 128,028 | 130.9 K to 128 K (-2.22 %) |
Feb 12 2021 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Buy | M | 0.00 | 8,134 | 0 | 130,934 | 122.8 K to 130.9 K (+6.62 %) |
Feb 12 2021 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Option Exercise | M | 0.00 | 32,795 | 0 | 65,589 | |
Feb 12 2021 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Option Exercise | M | 0.00 | 31,282 | 0 | 93,844 | |
Feb 12 2021 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Payment of Exercise | F | 49.84 | 16,259 | 810,349 | 502,831 | 519.1 K to 502.8 K (-3.13 %) |
Feb 12 2021 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Buy | M | 0.00 | 32,795 | 0 | 519,090 | 486.3 K to 519.1 K (+6.74 %) |
Feb 12 2021 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Payment of Exercise | F | 50.60 | 15,509 | 784,755 | 486,295 | 501.8 K to 486.3 K (-3.09 %) |
Feb 12 2021 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Buy | M | 0.00 | 31,282 | 0 | 501,804 | 470.5 K to 501.8 K (+6.65 %) |
Feb 01 2021 | GYHT | HALOZYME THERAPEUT ... | Kelley Kenneth J | Director | Sell | S | 48.69 | 246 | 11,977 | 189,833 | 190.1 K to 189.8 K (-0.13 %) |
Feb 01 2021 | GYHT | HALOZYME THERAPEUT ... | Kelley Kenneth J | Director | Sell | S | 48.09 | 4,754 | 228,617 | 190,079 | 194.8 K to 190.1 K (-2.44 %) |
Feb 01 2021 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Option Exercise | M | 14.66 | 50,000 | 733,000 | 600,000 | |
Feb 01 2021 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Sell | S | 48.51 | 5,437 | 263,736 | 470,522 | 476 K to 470.5 K (-1.14 %) |
Feb 01 2021 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Sell | S | 47.76 | 44,563 | 2,128,182 | 475,959 | 520.5 K to 476 K (-8.56 %) |
Feb 01 2021 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Buy | M | 14.66 | 50,000 | 733,000 | 520,522 | 470.5 K to 520.5 K (+10.63 %) |
Jan 04 2021 | GYHT | HALOZYME THERAPEUT ... | Kelley Kenneth J | Director | Sell | S | 43.38 | 290 | 12,581 | 194,833 | 195.1 K to 194.8 K (-0.15 %) |
Jan 04 2021 | GYHT | HALOZYME THERAPEUT ... | Kelley Kenneth J | Director | Sell | S | 42.88 | 4,710 | 201,974 | 195,123 | 199.8 K to 195.1 K (-2.36 %) |
Dec 21 2020 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Sell | S | 43.25 | 600 | 25,951 | 122,800 | 123.4 K to 122.8 K (-0.49 %) |
Dec 21 2020 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Sell | S | 42.54 | 11,400 | 484,967 | 123,400 | 134.8 K to 123.4 K (-8.46 %) |
Nov 30 2020 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Gift | G | 0.00 | 10,000 | 0 | 470,522 | 480.5 K to 470.5 K (-2.08 %) |
Nov 27 2020 | GYHT | HALOZYME THERAPEUT ... | Kelley Kenneth J | Director | Sell | S | 41.25 | 10,000 | 412,500 | 266,711 | 276.7 K to 266.7 K (-3.61 %) |
Nov 27 2020 | GYHT | HALOZYME THERAPEUT ... | Kelley Kenneth J | Director | Sell | S | 41.50 | 9,671 | 401,350 | 276,711 | 286.4 K to 276.7 K (-3.38 %) |
Nov 20 2020 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Sell | S | 39.04 | 7,889 | 307,955 | 134,800 | 142.7 K to 134.8 K (-5.53 %) |
Nov 20 2020 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Sell | S | 38.24 | 4,111 | 157,221 | 142,689 | 146.8 K to 142.7 K (-2.80 %) |
Oct 20 2020 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Sell | S | 30.43 | 12,000 | 365,148 | 146,800 | 158.8 K to 146.8 K (-7.56 %) |
Oct 20 2020 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Sell | S | 30.43 | 12,000 | 365,148 | 146,800 | 158.8 K to 146.8 K (-7.56 %) |
Sep 21 2020 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Sell | S | 26.91 | 12,000 | 322,884 | 158,800 | 170.8 K to 158.8 K (-7.03 %) |
Sep 14 2020 | GYHT | HALOZYME THERAPEUT ... | MATSUI CONNIE | Director | Gift | G | 0.00 | 8,000 | 0 | 208,753 | 216.8 K to 208.8 K (-3.69 %) |
Sep 14 2020 | GYHT | HALOZYME THERAPEUT ... | MATSUI CONNIE | Director | Sell | S | 27.06 | 32,000 | 865,792 | 216,753 | 248.8 K to 216.8 K (-12.86 %) |
Sep 04 2020 | GYHT | HALOZYME THERAPEUT ... | Matsuda Masaru | SVP, General Counse ... | Option Exercise | M | 0.00 | 6,884 | 0 | 13,766 | |
Sep 04 2020 | GYHT | HALOZYME THERAPEUT ... | Matsuda Masaru | SVP, General Counse ... | Payment of Exercise | F | 27.70 | 2,380 | 65,926 | 11,442 | 13.8 K to 11.4 K (-17.22 %) |
Sep 04 2020 | GYHT | HALOZYME THERAPEUT ... | Matsuda Masaru | SVP, General Counse ... | Buy | M | 0.00 | 6,884 | 0 | 13,822 | 6.9 K to 13.8 K (+99.22 %) |
Aug 20 2020 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Sell | S | 28.30 | 12,000 | 339,564 | 170,800 | 182.8 K to 170.8 K (-6.56 %) |
Aug 13 2020 | GYHT | HALOZYME THERAPEUT ... | Daly James M | Director | Sell | S | 29.12 | 34,337 | 999,893 | 31,365 | 65.7 K to 31.4 K (-52.26 %) |
Jul 20 2020 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Sell | S | 29.01 | 12,000 | 348,072 | 182,800 | 194.8 K to 182.8 K (-6.16 %) |
May 22 2020 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Option Exercise | M | 7.14 | 18,613 | 132,897 | 0 | |
May 22 2020 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Buy | M | 7.14 | 18,613 | 132,897 | 194,800 | 176.2 K to 194.8 K (+10.56 %) |
May 21 2020 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Option Exercise | M | 7.14 | 21,387 | 152,703 | 18,613 | |
May 21 2020 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Sell | S | 23.80 | 21,387 | 509,075 | 176,187 | 197.6 K to 176.2 K (-10.82 %) |
May 21 2020 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Buy | M | 7.14 | 21,387 | 152,703 | 197,574 | 176.2 K to 197.6 K (+12.14 %) |
May 01 2020 | GYHT | HALOZYME THERAPEUT ... | Posard Matthew L. | Director | Grant | A | 0.00 | 8,829 | 0 | 123,753 | 114.9 K to 123.8 K (+7.68 %) |
May 01 2020 | GYHT | HALOZYME THERAPEUT ... | MATSUI CONNIE | Director | Grant | A | 0.00 | 8,829 | 0 | 248,753 | 239.9 K to 248.8 K (+3.68 %) |
May 01 2020 | GYHT | HALOZYME THERAPEUT ... | Kelley Kenneth J | Director | Grant | A | 0.00 | 8,829 | 0 | 286,382 | 277.6 K to 286.4 K (+3.18 %) |
May 01 2020 | GYHT | HALOZYME THERAPEUT ... | Henderson Jeffrey William | Director | Grant | A | 0.00 | 8,829 | 0 | 72,107 | 63.3 K to 72.1 K (+13.95 %) |
May 01 2020 | GYHT | HALOZYME THERAPEUT ... | Daly James M | Director | Grant | A | 0.00 | 8,829 | 0 | 65,702 | 56.9 K to 65.7 K (+15.52 %) |
May 01 2020 | GYHT | HALOZYME THERAPEUT ... | Connaughton Bernadette | Director | Grant | A | 0.00 | 8,829 | 0 | 26,783 | 18 K to 26.8 K (+49.18 %) |
May 01 2020 | GYHT | HALOZYME THERAPEUT ... | BIZZARI JEAN-PIERRE | Director | Grant | A | 0.00 | 8,829 | 0 | 82,314 | 73.5 K to 82.3 K (+12.01 %) |
Apr 03 2020 | GYHT | HALOZYME THERAPEUT ... | Sun Elaine D | SVP, Chief Financia ... | Option Exercise | A | 0.00 | 40,796 | 0 | 40,796 | |
Mar 19 2020 | GYHT | HALOZYME THERAPEUT ... | Kelley Kenneth J | Director | Buy | P | 14.24 | 17,543 | 249,781 | 277,553 | 260 K to 277.6 K (+6.75 %) |
Mar 19 2020 | GYHT | HALOZYME THERAPEUT ... | Kelley Kenneth J | Director | Buy | P | 14.25 | 17,543 | 249,982 | 260,010 | 242.5 K to 260 K (+7.24 %) |
Mar 19 2020 | GYHT | HALOZYME THERAPEUT ... | Kelley Kenneth J | Director | Buy | P | 14.19 | 17,543 | 248,933 | 242,467 | 224.9 K to 242.5 K (+7.80 %) |
Mar 04 2020 | GYHT | HALOZYME THERAPEUT ... | Sun Elaine D | SVP, Chief Financia ... | Option Exercise | A | 0.00 | 48,662 | 0 | 48,662 | |
Mar 04 2020 | GYHT | HALOZYME THERAPEUT ... | Sun Elaine D | SVP, Chief Financia ... | Option Exercise | A | 20.55 | 104,969 | 2,157,113 | 104,969 | |
Feb 24 2020 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Option Exercise | M | 0.00 | 8,803 | 0 | 8,803 | |
Feb 24 2020 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Payment of Exercise | F | 21.83 | 3,044 | 66,451 | 176,187 | 179.2 K to 176.2 K (-1.70 %) |
Feb 24 2020 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Buy | M | 0.00 | 8,803 | 0 | 179,231 | 170.4 K to 179.2 K (+5.17 %) |
Feb 24 2020 | GYHT | HALOZYME THERAPEUT ... | Stelzer Laurie | SVP, Chief Financia ... | Option Exercise | M | 0.00 | 11,392 | 0 | 11,392 | |
Feb 24 2020 | GYHT | HALOZYME THERAPEUT ... | Stelzer Laurie | SVP, Chief Financia ... | Payment of Exercise | F | 21.83 | 4,508 | 98,410 | 116,167 | 120.7 K to 116.2 K (-3.74 %) |
Feb 24 2020 | GYHT | HALOZYME THERAPEUT ... | Stelzer Laurie | SVP, Chief Financia ... | Buy | M | 0.00 | 11,392 | 0 | 120,675 | 109.3 K to 120.7 K (+10.42 %) |
Feb 24 2020 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Option Exercise | M | 0.00 | 39,354 | 0 | 39,354 | |
Feb 24 2020 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Payment of Exercise | F | 21.83 | 19,511 | 425,925 | 490,522 | 510 K to 490.5 K (-3.83 %) |
Feb 24 2020 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Buy | M | 0.00 | 39,354 | 0 | 510,033 | 470.7 K to 510 K (+8.36 %) |
Feb 18 2020 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Option Exercise | M | 0.00 | 5,772 | 0 | 11,542 | |
Feb 18 2020 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Payment of Exercise | F | 21.10 | 1,995 | 42,095 | 170,428 | 172.4 K to 170.4 K (-1.16 %) |
Feb 18 2020 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Buy | M | 0.00 | 5,772 | 0 | 172,423 | 166.7 K to 172.4 K (+3.46 %) |
Feb 18 2020 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Option Exercise | M | 0.00 | 28,730 | 0 | 57,458 | |
Feb 18 2020 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Payment of Exercise | F | 21.10 | 14,244 | 300,548 | 470,679 | 484.9 K to 470.7 K (-2.94 %) |
Feb 18 2020 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Buy | M | 0.00 | 28,730 | 0 | 484,923 | 456.2 K to 484.9 K (+6.30 %) |
Feb 13 2020 | GYHT | HALOZYME THERAPEUT ... | Matsuda Masaru | SVP, General Counse ... | Option Exercise | M | 0.00 | 4,130 | 0 | 12,387 | |
Feb 13 2020 | GYHT | HALOZYME THERAPEUT ... | Matsuda Masaru | SVP, General Counse ... | Payment of Exercise | F | 20.00 | 1,681 | 33,620 | 6,938 | 8.6 K to 6.9 K (-19.50 %) |
Feb 13 2020 | GYHT | HALOZYME THERAPEUT ... | Matsuda Masaru | SVP, General Counse ... | Buy | M | 0.00 | 4,130 | 0 | 8,619 | 4.5 K to 8.6 K (+92.00 %) |
Feb 13 2020 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Option Exercise | M | 0.00 | 7,883 | 0 | 23,649 | |
Feb 13 2020 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Payment of Exercise | F | 20.00 | 2,725 | 54,500 | 166,651 | 169.4 K to 166.7 K (-1.61 %) |
Feb 13 2020 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Buy | M | 0.00 | 7,883 | 0 | 169,376 | 161.5 K to 169.4 K (+4.88 %) |
Feb 13 2020 | GYHT | HALOZYME THERAPEUT ... | Stelzer Laurie | SVP, Chief Financia ... | Option Exercise | M | 0.00 | 11,262 | 0 | 0 | |
Feb 13 2020 | GYHT | HALOZYME THERAPEUT ... | Stelzer Laurie | SVP, Chief Financia ... | Payment of Exercise | F | 20.00 | 3,894 | 77,880 | 104,174 | 108.1 K to 104.2 K (-3.60 %) |
Feb 13 2020 | GYHT | HALOZYME THERAPEUT ... | Stelzer Laurie | SVP, Chief Financia ... | Buy | M | 0.00 | 11,262 | 0 | 108,068 | 96.8 K to 108.1 K (+11.63 %) |
Feb 13 2020 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Option Exercise | M | 0.00 | 32,795 | 0 | 98,384 | |
Feb 13 2020 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Payment of Exercise | F | 20.00 | 16,259 | 325,180 | 456,193 | 472.5 K to 456.2 K (-3.44 %) |
Feb 13 2020 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Buy | M | 0.00 | 32,795 | 0 | 472,452 | 439.7 K to 472.5 K (+7.46 %) |
Feb 12 2020 | GYHT | HALOZYME THERAPEUT ... | Matsuda Masaru | SVP, General Counse ... | Option Exercise | A | 0.00 | 25,026 | 0 | 25,026 | |
Feb 12 2020 | GYHT | HALOZYME THERAPEUT ... | Matsuda Masaru | SVP, General Counse ... | Option Exercise | A | 19.98 | 53,211 | 1,063,156 | 53,211 | |
Feb 12 2020 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Option Exercise | A | 0.00 | 32,533 | 0 | 32,533 | |
Feb 12 2020 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Option Exercise | A | 19.98 | 69,174 | 1,382,097 | 69,174 | |
Feb 12 2020 | GYHT | HALOZYME THERAPEUT ... | Stelzer Laurie | SVP, Chief Financia ... | Option Exercise | A | 0.00 | 32,533 | 0 | 32,533 | |
Feb 12 2020 | GYHT | HALOZYME THERAPEUT ... | Stelzer Laurie | SVP, Chief Financia ... | Option Exercise | A | 19.98 | 69,174 | 1,382,097 | 69,174 | |
Feb 12 2020 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Option Exercise | A | 0.00 | 125,126 | 0 | 125,126 | |
Feb 12 2020 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Option Exercise | A | 19.98 | 266,051 | 5,315,699 | 266,051 | |
Feb 04 2020 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Option Exercise | M | 0.00 | 11,559 | 0 | 0 | |
Feb 04 2020 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Payment of Exercise | F | 19.21 | 4,289 | 82,392 | 161,493 | 165.8 K to 161.5 K (-2.59 %) |
Feb 04 2020 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Buy | M | 0.00 | 11,559 | 0 | 165,782 | 154.2 K to 165.8 K (+7.49 %) |
Feb 04 2020 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Option Exercise | M | 0.00 | 55,487 | 0 | 0 | |
Feb 04 2020 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Payment of Exercise | F | 19.21 | 19,910 | 382,471 | 439,657 | 459.6 K to 439.7 K (-4.33 %) |
Feb 04 2020 | GYHT | HALOZYME THERAPEUT ... | Torley Helen | President and CEO | Buy | M | 0.00 | 55,487 | 0 | 459,567 | 404.1 K to 459.6 K (+13.73 %) |
Feb 04 2020 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Option Exercise | M | 0.00 | 11,559 | 0 | 0 | |
Feb 04 2020 | GYHT | HALOZYME THERAPEUT ... | LaBarre Michael J. | SVP, Chief Technica ... | Payment of Exercise | F | 19.21 | 4,289 | 82,392 | 161,493 | 165.8 K to 161.5 K (-2.59 %) |